Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Gastrointestinal 3Breast 3Gynecologic 1

Conditions

Colorectal Neoplasms 55Neoplasms 31Unspecified Adult Solid Tumor, Protocol Specific 30Pancreatic Neoplasms 28Neoplasm Metastasis 24Colonic Neoplasms 23Stomach Neoplasms 22Rectal Neoplasms 20Neuroblastoma 15Lung Neoplasms 13Esophageal Neoplasms 12Glioblastoma 11Central Nervous System Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 11Astrocytoma 11Small Cell Lung Carcinoma 9Glioma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma 7Unspecified Childhood Solid Tumor, Protocol Specific 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Hepatocellular 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Solid Tumor 5

Interventions

Cisplatin 35pembrolizumab 29Radiotherapy 26Cetuximab 26Docetaxel 17Paclitaxel 13Fluorouracil 13Cyclophosphamide 12fludarabine 11Radiotherapy, Intensity-Modulated 11Nivolumab 10Carboplatin 9atezolizumab 7Radiation 7Gemcitabine 7Erlotinib Hydrochloride 7Bortezomib 7fludarabine phosphate 6Pemetrexed 5Interleukin-2 5Radiosurgery 4Everolimus 4Drug Therapy 4Azacitidine 4olaparib 3motexafin gadolinium 3durvalumab 3cemiplimab 3Trastuzumab 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Head and Neck Neoplasms × Irinotecan × Clear all
NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

SN BioScience

Phase 1 Completed
21 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT01520389 2018-03-21

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Merrimack Pharmaceuticals

Phase 1 Completed
112 enrolled
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡